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INTRODUCTION
Statin prescriptions for those at high 
cardiovascular risk have widely been seen 
as an important contributor to reducing 
the population burden of heart disease.1 
Such strategies rely on GPs identifying 
those at higher risk, and communicating 
the benefits of medication to patients. A 
large body of research now addresses how 
to communicate risk information,2 and a 
growing evidence base is emerging on how 
best to present patients with quantitative 
information about risk in general 
practice.3–6 This evidence suggests that 
information about risks is best presented 
quantitatively, as event rates,2 although 
GPs may prefer qualitative rather than 
quantitative presentations of risk.3 Evidence 
that presenting numeric information to 
patients improves risk comprehension4 
has influenced good-practice guidance for 
developing decision aids for patients.6
Most evaluative research about risk 
communication formats has used accurate 
recall of information and comprehension 
as end points.2,4,7 However, there is less 
research about how such cognitive risk 
understanding is used in practice; that 
is, once people have the information and 
comprehend it, how will they use this 
knowledge to make decisions? Patients’ 
general views of preventive medication use 
have been widely researched, with reported 
reservations about taking hypertensive 
medication8 reflecting reservations found 
for long-term and preventive medications 
in general.9 In the light of recent interest 
in risk communication, there is a need for 
more research on the specific question 
of what use is made of quantitative risk 
information in decision making about 
preventive medication. This article 
addresses this question through analysis of 
qualitative data generated in a study of how 
people make decisions about taking statins.
METHOD
Setting and participants
Thirty-four participants aged >50 years 
were recruited and interviewed face-to-
face in community settings, most in their 
homes, in East Anglia between 2011 and 
2013. Invitations to participate were made 
through community groups such as lunch 
clubs and an exercise class, and snowballing 
from initial participants to identify those 
offered statins. All participants had been 
offered a statin for either primary (n = 17) 
or secondary prevention (n = 17); over 
half (n = 22) were currently taking statins. 
Participants were aged 53–87 years.
Data generation
Twenty-two participants were interviewed 
in couples, and 12 in individual interviews. 
An advantage of pair interviews, which 
generate less formal accounts than are 
often generated in one-to-one interviews, 
is that they provide some access to how 
participants talk within the everyday 
L Polak, PhD student and GP, MRCP (Paeds), 
MRCGP Department of Health Services Research 
and Policy, London School of Hygiene and Tropical 
Medicine, London, and North Hill Medical Group, 
Colchester. J Green, BSc, MSc, PhD, professor of 
sociology of health, Department of Health Services 
Research and Policy, London School of Hygiene 
and Tropical Medicine, London.
Address for correspondence
Louisa Polak, Department of Health Services 
Research and Policy, London School of Hygiene 
and Tropical Medicine, 15–17 Tavistock Place, 
London WC1H 9SH.
E-mail: louisa.polak@lshtm.ac.uk
Submitted: 6 August 2014; Editor’s response:  
14 September 2014; final acceptance: 28 October 
2014.
©British Journal of General Practice
This is the full-length article (published online  
30 Mar 2015) of an abridged version published 
in print. Cite this article as: Br J Gen Pract 2015;  
DOI: 10.3399/bjgp15X684433
Using quantitative risk information in 
decisions about statins:
a qualitative study in a community setting
Louisa Polak and Judith Green
Research
Abstract
Background 
A large literature informs guidance for 
GPs about communicating quantitative risk 
information so as to facilitate shared decision 
making. However, relatively little has been 
written about how patients utilise such 
information in practice.
Aim
To understand the role of quantitative risk 
information in patients’ accounts of decisions 
about taking statins. 
Design and setting
This was a qualitative study, with participants 
recruited and interviewed in community 
settings.
Method
Semi-structured interviews were conducted 
with 34 participants aged >50 years, all of 
whom had been offered statins. Data were 
analysed thematically, using elements of the 
constant comparative method.
Results
Interviewees drew frequently on numerical 
test results to explain their decisions about 
preventive medication. In contrast, they seldom 
mentioned quantitative risk information, 
and never offered it as a rationale for action. 
Test results were spoken of as objects of 
concern despite an often-explicit absence 
of understanding, so lack of understanding 
seems unlikely to explain the non-use of risk 
estimates. Preventive medication was seen 
as ‘necessary’ either to treat test results, or 
because of personalised, unequivocal advice 
from a doctor. 
Conclusion
This study’s findings call into question 
the assumption that people will heed and 
use numerical risk information once they 
understand it; these data highlight the need 
to consider the ways in which different kinds 
of knowledge are used in practice in everyday 
contexts. There was little evidence from 
this study that understanding probabilistic 
risk information was a necessary or valued 
condition for making decisions about statin use.
Keywords
decision making, shared; general practice; 
prevention; risk; statins, HMG-CoA.
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contexts within which decisions are made. 
Paired interviews also have an advantage 
over private interviews as they allow 
participants to discuss issues that may 
be sensitive within relationships (such 
as fear of future ill health). All interviews 
were conducted by the one author, who 
introduced herself as a local GP doing a 
research project that was separate from 
her practice work. None of the interviewing 
GP’s patients were invited to participate. All 
interviews were recorded and transcribed 
verbatim. Interviews were semi-structured, 
using a brief topic guide, and lasted 23–87 
minutes. Prompts included questions on 
participants’ state of health, where their 
knowledge about health came from, 
how they looked after their health, use of 
medication, and deciding whether to take 
statins.
Analysis
Analysis drew on elements of the constant 
comparative method,10 beginning with 
in-depth line-by-line coding of early data, 
and comparisons within the data and 
with the literature to generate provisional 
explanations. Coding and memos were 
recorded using multiple Microsoft® Word 
documents. Codes were refined by relating 
them to subsequent batches of data and 
further reading of relevant literature, in an 
iterative process aiming to build a robust 
and potentially generalisable account: ‘a 
plausible story about what is going on’.11 
Throughout this process, rigour was 
increased by regular discussion about 
coding decisions and analytic direction. In 
this study, all names are pseudonyms and 
identifying material has been removed.
RESULTS
Initial thematic analysis elicited a surprising 
fact: although people’s accounts were full 
of numbers describing health or health 
behaviours, there were almost no instances 
where numbers were used to talk about 
risk or prevention. Further analysis was 
directed towards explaining this contrast, 
by comparing the way numerical test 
results were used with the way risk and 
prevention were talked about.
Using quantitative information: ‘magic 
numbers’
Participants’ accounts contained varied 
and frequent references to numbers 
related to health and health care, including 
numeric indicators of weight, blood 
pressure, medication dosage, and blood 
test results. A common use of numbers 
was for making comparative assessments 
in relation to, for instance, their past self, 
or other people:
‘All I know is my blood pressure is a lot 
lower than it used to be, because it used to 
be 180/90 … and is now 118/60.’ (Peter)
A second use of numeric values was 
as triggers for action. Here, participants 
used specific numbers as thresholds or 
goals when talking about the way they 
took decisions about health behaviours or 
healthcare use:
‘Since I’ve been on the statins it’s down to 
about 2 or 2.5, which is where they want it 
to be with my situation.’ (Larry)
‘They said it was about 6.9 and they put me 
on Bezalip®.’ (Debbie)
These examples are typical in that the 
rationale for choosing a particular number 
as a goal or trigger was seldom mentioned 
or queried. Often the source for the figure 
was (as in these examples) a generic ‘they’ 
rather than a specific doctor, and the value 
itself was recalled hesitantly, suggesting 
uncertainty:
Claire: They put [Walter] on statins a few 
months ago and I think his cholesterol is 
what, 2.9?’ 
Walter: ‘4.2 … that is good or something, I 
don’t know what it all means, but 4.’ 
However, if the rationale for numbers 
was mysterious, they were tacitly accepted, 
even powerful, forces for eliciting action. As 
Henry’s mention of the ‘magic’ power of ‘5’ 
suggests:
‘Every time it has been mentioned it has 
How this fits in
Much is written about the best way to 
present quantitative risk information to 
patients, as clinicians are encouraged 
to do. Less research considers how 
such information is utilised in practice. 
In this study of interviewees’ accounts 
of their decisions about statins, risk 
estimates were hardly mentioned and 
never described as influential. If replicated 
elsewhere, this raises the question 
whether communicating quantitative 
risk information should remain a central 
component of endeavours to facilitate 
shared decision making.
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been below the magic figure, the 5 ... 
5.5, I can’t remember which it is, anyway 
whatever it is there is a threshold and it has 
been below the threshold.’ (Henry)
That such numbers had an esoteric 
element did not mean patients were 
resistant to scientific evidence. Indeed, the 
roots of the numbers in ‘hard evidence’ 
were an essential factor in their authority 
for some, as suggested by Don’s citation 
of ‘chemistry’ in his exchange with his wife 
Mary:
Don: ‘I’m happy to take them, and just watch 
the hard evidence of the blood test every 
6 months just to see what’s happening, to 
that cholesterol, level … I would go very 
much by, you know, what ... those blood 
levels are telling me.’
Mary: ‘Yeah, what your body’s doing.’
Don: ‘Exactly. Because I understand that … 
er, there is a lot of chemistry there [laughs] 
… and it’s … what those results actually tell 
me, that lead me down a particular avenue 
… of taking medication, or not.’
In a few extreme instances, the power 
of numbers as effective triggers to action 
persisted even though the construct being 
measured was not explicitly mentioned. In 
their account of Peter’s hospital admission 
and treatment, for instance, Wendy and 
Peter carefully recall numbers, but it is 
opaque (at least to an outsider) to what ‘the 
numbers’ that triggered action referred:
Wendy: ‘You had, what was it? It was 0.02.’
Peter: ‘Should be 0.02.’ 
Wendy: And yours was 8.’ 
Peter: ‘8.5.’ 
Wendy: ‘And then Dr Jones said, when 
we get to 54 then we start to be a bit 
concerned.’ 
In summary, quantitative information 
was widely cited, and recalled as effective 
in triggering action even where participants 
drew on limited knowledge of what the 
numbers were measuring or understanding 
of how threshold levels were chosen. 
So it seems unlikely that understanding, 
knowledge, or recall about quantitative 
information is a necessary condition for 
making a health-related decision, such as 
taking statins.
Knowing but not using quantitative risk 
information
In the few deviant cases where numerical 
risk information was mentioned in 
interviews, there was little evidence that 
it had any particular salience for decision 
making. Two excerpts from these atypical 
cases illustrate this. First, Bill recalls his 
risk of heart disease, but his subsequent 
comment suggests that what was 
significant for his decision was not this 
quantitative estimate, but the inference that 
this was ‘normal’, in that he was in the 
middle of a range and like other people 
his age:
‘I think I’m on 11% chance of a heart issue 
in the next 5 years, or something — is that 
the one? Is that the statistic which is about 
in the middle isn’t it, I think, for men of my 
age? So — I think that’s all right.’ (Bill)
Second, Barbara also described her 
understanding of numerical risk estimates 
for heart disease as recalled from her GP’s 
account. However, the hesitancy of both 
her recollection and decision suggest that 
these probabilistic figures were not a major 
influence on her decision to take statins. 
Again, her interview suggested that this 
did not reflect a lack of responsiveness to 
quantification in general, in that cholesterol 
readings, in contrast, were reported as 
being a deciding factor:
‘He said perhaps I ought to think about going 
on statins, and he showed me a display on 
his computer screen, of a hundred hearts, 
you know showing up percentages and 
telling me that if I took them for 10 years 
I would reduce my risk by 4%, from 18 to 
14%, or something like that … I think those 
were the figures. So … er … I wasn’t quite 
sure whether I wanted to — it didn’t seem 
a huge … er, difference to me, really … the 
4%.’ (Barbara)
But later: 
‘People talk about different numbers, er, 
and you don’t really know what they mean, 
but, my cholesterol had gone up to 9 or 
something … so I thought perhaps I ought 
to do something about it.’ (Barbara)
Talking about risk and prevention
The rarity with which quantitative risk 
information appeared in the data cannot be 
explained by a lack of talk about or interest 
in reasons to take preventive medication. 
Indeed, such talk was very prevalent, 
prompted by the topic guide, but also raised 
spontaneously:
Prevention is the ideal, and everything 
else is, kind of backing up when things go 
wrong.’ (Eric)
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‘I think they just said … something to take 
now, to help you for the future.’ (Simon)
Explanations like Simon’s, resting simply 
on being advised that action now would 
lead to benefit in future, were common. 
However, the probability of experiencing 
this benefit was rarely mentioned at all 
in the interview data, and never reported 
numerically. If future risks were mentioned, 
it was in generic, non-numeric, terms:
‘The doctor said to [my husband], you know, 
with blood pressure like this, untreated, you 
would have a major stroke or heart attack … 
which could well be fatal.’ (Hazel)
Further, when asked explicitly, patients 
rejected the idea that probabilistic 
quantification would be a useful aid:
Don: ‘It would have to be a very … personal 
thing, and a GP would have to say ‘Yes! 
aspirins would definitely help … your 
particular case.’ 
Interviewer: ‘Right. So ‘Out of 100 people 
exactly like you they’ll help 10’ wouldn’t 
do it?’ 
Don: ‘No. Exactly, that’s right.’ 
Two elements appear important here: a 
personalised message and certainty about 
the future. Messages recalled as being 
personal and deterministic were reported 
as persuasive, as in Larry’s account:
‘He pointed his finger at me and he said ‘If 
you want to live a normal life you take the 
tablets and you’ll live to be an old man … 
Don’t take the tablets and who knows what 
will happen.’ So, I have always taken my 
tablets.’ (Larry)
Several other interviewees spoke of 
these elements as essential if advice is to 
trigger action:
I don’t particularly like … being put on a 
regimen of drugs which has been designed 
for an average person, or a person who falls 
into a very, very, very large category.’ (Geoff)
‘I think we would all be happy to take 
some things … if we were absolutely 
convinced that it was necessary, but if it is 
just a possible thing then you have to think 
carefully about it.’ (Liz)
Quantitative risk information was not, 
it seems, relevant to these two significant 
components of persuasive knowledge. It 
was, by definition, related to the population 
as a whole, not the individual, and it could 
not be deterministic.
DISCUSSION
Summary
Quantitative information about risk was 
not used in participants’ accounts of how 
they made the decision about statins. Our 
analysis suggests that this lack of salience 
does not reflect lack of knowledge, or 
aversion to quantitative data in general, as 
other numbers (such as cholesterol levels) 
were widely cited as decisive triggers for 
action. What did trigger decisions to take 
risk-reducing medication was unequivocal, 
personalised advice from a doctor.
Strengths and limitations
Key strengths of this study were that it 
included both those who did and those who 
did not decide to take statins, and that it 
drew on patients’ accounts generated in the 
settings in which decisions about medication 
use are likely to be made: the home and 
between partners. Couple interviews in 
particular captured the ‘everyday’ talk that 
underpins people’s day-to-day decision 
making. The study was limited to residents 
in East Anglia, a region with relatively low 
heterogeneity with regard to ethnicity and 
socioeconomic status; the generalisability 
of the conclusions to other contexts 
remains to be tested. That the interviews 
were conducted by a GP had potential 
disadvantages in that patients may have 
been either more reluctant or more anxious 
to demonstrate detailed understanding of 
‘medical’ matters. This was addressed in 
the analysis by careful consideration of how 
the interviewer’s expertise was attended 
to in responses, and by comparing the 
findings with those from other studies.
Comparison with existing literature
The contrast between the widespread 
citation of test results as important for 
decision making and the almost non-
existent use of quantitative risk information 
in patients’ accounts has not previously 
been highlighted in the literature. The 
scarcity of risk estimates in the data is 
surprising from a perspective grounded 
in the risk communication literature. 
However, this finding is perhaps less 
surprising in the light of a large body of 
other research which suggests that 
people’s health decisions in general rely 
less on probabilistic future risk estimates, 
and more on advice that is regarded as 
applying to them personally,12–17 and given 
to them personally by a doctor.8,18–22 Indeed, 
Gale et al found that even people who had 
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been taught how to interpret the results of 
risk calculations, and who demonstrably 
understood them, did not base decisions 
on them, preferring to ask their doctor 
what to do.20 This poses a challenge to the 
assumption implicit in much biomedical 
writing about risk communication2 that 
people will heed and use numerical 
information once they understand it.
That participants do not mention risk 
estimates when talking about preventive 
medication, or do not use them as rationales 
for action, does not of course necessarily 
mean that these are not part of the useful 
backdrop of knowledge that patients draw 
on in making complex decisions about 
medication use. It is perhaps rare that 
healthcare decisions are made by patients 
acting simply as the ‘rational choice 
agents’ addressed by decision aids and 
described in game theory,23 and in practice 
a rather broader array of knowledge 
sources and values are brought into any 
particular decision. Davison et al’s classic 
work on risk, for instance, identified a ‘lay 
epidemiology’ in which knowledge about 
coronary candidacy combined theoretical 
with experiential knowledge of known 
others who, for instance, lived to be 100 
despite heavy smoking.24 Thus there was 
widespread implicit knowledge of the 
prevention paradox that interventions which 
benefit populations may harm individuals, 
and of the ‘irreducible uncertainty’ of an 
individual’s future, however definitely 
statisticians predict outcomes for a large 
population.25 
Others26–28 have since examined the way 
that people use their practical knowledge 
alongside theoretical knowledge29 from a 
variety of sources, to produce ‘rules of 
thumb’ that guide their health decisions; 
for example, about food choices or taking 
aspirin. In the process of combining 
different kinds of knowledge to produce 
these rules, theoretical knowledge about 
risk levels is undermined by tacit practical 
knowledge that the future is uncertain. 
As Rapley suggests, decisions in practice 
are ‘distributed’, in that they are ongoing 
events involving multiple encounters and 
places.30
This study’s data suggest that test 
results are widely heeded: they are facts 
about the present, and can be incorporated 
into an assessment of one’s state of health 
alongside facts like looking pale or feeling 
pain.31,32 It seems plausible that the salience 
of risk estimates is limited because they 
are facts about the future, inherently 
impersonal and uncertain. In building the 
body of practical knowledge that informs 
everyday decisions,33 such as taking long-
term medication, facts about the future 
may not get a strong foothold, however well 
they are understood.
Implications for research and practice
Significant developments in research 
on cognitive understanding of risk 
communication have not been matched by 
our understanding of how such knowledge 
is used in practice by patients in making 
decisions about the use of medications such 
as statins. The finding that people seldom 
use quantitative risk information in making 
decisions about preventive interventions, 
if replicated elsewhere, raises significant 
questions for both research and practice. 
Should communicating quantitative 
information remain a central component of 
clinicians’ endeavours to facilitate shared 
decision making?34 And should researchers 
working to make this communication 
more effective look at outcomes beyond 
‘knowledge and understanding’?
If a painstaking discussion of numerical 
risk information has little or no effect on 
the patient’s decision, a cash-limited health 
service may decide to look for shortcuts 
to a patient-centred approach.35 One such 
shortcut might be found by following Elwyn 
et al’s recommendation to offer a choice 
about participation in decision making.36 For 
instance, saying ‘I would suggest you give 
statins a try, so as to make you less likely 
to have heart attacks in future — would 
you like me to show you the statistics about 
that?’ may often elicit the reply ‘No thanks’, 
shortening the consultation without making 
any difference to its outcomes.
Such an approach is arguably more 
patient-centred than attempts to ‘engage … 
patients in risk management discussions’,5 
because it recognises a potential 
misunderstanding that may undermine the 
project of risk communication in the context 
of prevention. To a clinician, preventive 
medication is synonymous with risk-
reducing medication, but this small study 
suggests that patients may not consider 
‘prevention’ in quite the same way. At least 
in the context of preventive medication, 
some people may not base decisions on the 
probabilities of various possible outcomes, 
however effectively those probabilities are 
explained or carefully weighted to reflect 
individual preferences and values.
In summary, recommended approaches 
to communicating about risk are 
challenged by this study’s finding that 
patients make minimal use of quantitative 
risk estimates when talking about 
preventive medication.
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